Background: For HRþ/HER2-metastatic breast cancer (mBC), international guidelines recommend the use of endocrine therapy (ET) as first-line (L1) treatment except in case of "visceral crisis" for which chemotherapy (CT) is advised. Few studies directly compare these two treatment options. In 2014, UNICANCER launched the Epidemiological Strategy and Medical Economics (ESME) Research program to centralize real-world data in oncology. We sought to use this database to study this question. Methods: All patients (pts) who initiated treatment for a newly diagnosed mBC between January 2008 and December 2014 in all 18 French Comprehensive Cancer Centers were included in the ESME mBC database. ESME Research program centralized all existing data using retrospective data collection. Primary endpoint of the present study was progression free survival (PFS1) and overall survival (OS) according to L1 treatment for aromatase inhibitors sensitive (AIS) HRþ/HER2-mBC pts. Results: 6265 pts out of 16703 in ESME, had AIS HRþ/HER2-mBC. As L1 therapy, 2733 pts (43.6%) received ET alone, while 3532 received CT (56.4%). Among these 3532 pts, 2073 (58.7%) received ET as maintenance treatment after CT. A Cox multivariate analysis with significant prognostic variables identified a lower risk of death in the patients with L1 ET (HR ¼ 0.839, 95% IC [0.772-0.911], p < 0.0001). Patients receiving CT were younger (median age 56.0 vs 66.0, p < 0.001), more likely to have visceral metastasis (61.6% vs 40.1%, p < 0.001) and SBR III primary tumors (31.3% vs 18.8%, p < 0.001). Median PFS1 was 15.18 months for L1 ET (95% CI, 14.45-16.20) vs 12.58 months for L1 CT þ/-hormone maintenance (95% CI, 11.89-13.14), p < 0.0001. Median OS was 60.78 months for L1 ET (95% CI, 57.16-64.09) vs 49.64 months for L1 CT (95% CI, 47.31-51.64), p < 0.0001.
Background: For HRþ/HER2-metastatic breast cancer (mBC), international guidelines recommend the use of endocrine therapy (ET) as first-line (L1) treatment except in case of "visceral crisis" for which chemotherapy (CT) is advised. Few studies directly compare these two treatment options. In 2014, UNICANCER launched the Epidemiological Strategy and Medical Economics (ESME) Research program to centralize real-world data in oncology. We sought to use this database to study this question. Methods: All patients (pts) who initiated treatment for a newly diagnosed mBC between January 2008 and December 2014 in all 18 French Comprehensive Cancer Centers were included in the ESME mBC database. ESME Research program centralized all existing data using retrospective data collection. Primary endpoint of the present study was progression free survival (PFS1) and overall survival (OS) according to L1 treatment for aromatase inhibitors sensitive (AIS) HRþ/HER2-mBC pts. Results: 6265 pts out of 16703 in ESME, had AIS HRþ/HER2-mBC. Background: The everolimus-exemestane combination has been included in the International guidelines for advanced HRþ breast cancer (mBC) since the results of the Bolero-2 trial. Marketing authorization has been granted in France in July 2012. We evaluated the incidence and indication of everolimus (EVE) use before and after marketing authorization and reimbursement. Methods: All patients who initiated treatment for a newly diagnosed mBC between 01/ 2008 and 12/2015 in all 18 French Comprehensive Cancer Centers have been included in the real life ESME database, which collects retrospective data using a clinical triallike methodology. Results: The ESME program included a total of 16,703 patients of which 9,921 had HRþ/HER2-mBC. Median age at metastatic diagnosis was 62.0 year (range 23-96). Visceral metastases were present in 60.3% of cases. Only 4123 patients (41.6%) received endocrine therapy alone as first-line therapy, and 60% were deemed endocrine resistant. Overall, 1,217 (12.3%) pts have received EVE during therapy as of Dec. 2015 (all lines). EVE was given as first line therapy in 117 pts (10% of all EVE pts and 1.2% of pts receiving a first line therapy). In 99/117 pts (85%) EVE was combined with exemestane. Before 2012, EVE was used within clinical trials. After 2012, use of EVE increased steadily. Percentages in the Table refer to the total of pts who received any kind of treatment during a given year of observation (eg 506 pts took EVE in 2015 out of 4435). Median duration of EVE use was 6.0 months (range 0-65) as first line treatment and 3.9 months (range 0-65) in pretreated patients. Patient population and causes of EVE cessation will be detailed at the meeting.
Conclusions:
In this very large French national and representative cohort of HRþ HER2-mBC, EVE use rose quickly as soon as marketed. EVE was mostly used in pretreated mBC albeit in probably too advanced pts. These data underline the need for physician and patient education for oral therapies. Legal entity responsible for the study: UNICANCER R&D Funding: UNICANCER Disclosure: All authors have declared no conflicts of interest. Background: Although several recent trials have demonstrated improved progressionfree survival (PFS) or time to progression (TTP) with first-line regimens for HER2-negative mBC, OS benefit is often elusive. We calculated required sample sizes to power for OS based on published data in recent trials. Methods: Randomised superiority trials of first-line chemotherapy or targeted therapy for HER2-negative mBC including >150 patients, meeting the primary efficacy objective and published between 2000 and 2014 were identified. The sample sizes required to power for PFS (or TTP) and OS were calculated retrospectively for each trial using the observed results and study/recruitment follow-up durations (alpha¼0.05, 2-sided logrank test, 80% power), and summarised as a factor relative to the actual sample size (x < 1 required x-fold fewer cases to show the same gain; x > 1 required x-fold more cases). Results: Only 8 of the 14 identified trials reported all information required for retrospective sample size calculation (Table) . Most would have required a far larger sample size to demonstrate an OS gain (x: 0.5-2479) with the observed results. In 10 of 13 trials, the sample size required to power for OS was at least 5-fold larger than that needed to power for PFS. Conclusions: Designing trials to test potential new treatments for HER2-negative mBC is challenging and requires a balance of regulatory acceptability, feasibility and realistic medical assumptions to calculate sample sizes, which can be particularly difficult in heterogeneous study populations with long post-progression survival and heterogeneous subsequent therapies. However, ongoing and future trials of cancer immunotherapy (new mode of action) focusing on triple-negative mBC (a more homogeneous population with shorter OS and post-progression survival, and fewer treatment options) may show a new pattern. 
